Sector Expert: George Zavoico


Image: George Zavoico

Dr. George Zavoico, senior equity analyst at JonesTrading Institutional Services LLC, has more than 10 years of experience as a life sciences equity analyst writing research on publicly traded equities. His principal focus is on biotechnology, biopharmaceutical, specialty pharmaceutical, and molecular diagnostics companies. Previously, Zavoico was a senior equity research analyst in the healthcare sector at MLV & Co., and an equity analyst at Cantor Fitzgerald and Westport Capital Markets. Prior to becoming an equity analyst, Zavoico established his own consulting company serving the biotech and pharmaceutical industries, providing competitive intelligence and marketing research, due diligence services and guidance in regulatory affairs. Zavoico began his career as a senior research scientist at Bristol-Myers Squibb Co., moving on to management positions at Alexion Pharmaceuticals Inc. and T Cell Sciences Inc. (now Celldex Therapeutics Inc.). Zavoico has a bachelor's degree in biology from St. Lawrence University and a Ph.D. in physiology from the University of Virginia. He held post-doctoral fellowships at the University of Connecticut School of Medicine and Harvard Medical School/Brigham & Women's Hospital. He has published more than 30 papers in peer-reviewed journals and has coauthored four book chapters. He received The Financial Times/Starmine Award two years in a row for being among the top-ranked earnings estimators in the biotechnology sector.

Subscribe to
Streetwise Reports

Companies Commented On

  • Abeona Therapeutics Inc.
  • ADMA Biologics Inc.
  • Aduro Biotech Inc.
  • Agenus Inc.
  • Akebia Therapeutics Inc.
  • Amgen Inc.
  • Applied Genetic Technologies Corp.
  • Array BioPharma Inc.
  • Asterias Biotherapeutics Inc.
  • Can-Fite BioPharma Ltd.
  • Compugen Ltd.
  • CTI BioPharma
  • Emergent BioSolutions Inc.
  • Evoke Pharma Inc.
  • Fate Therapeutics Inc.
  • FlexPharma
  • Galena Biopharma Inc.
  • Ignyta Inc.
  • Inovio Pharmaceuticals Inc.
  • Juno Therapeutics
  • Kite Pharma
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • Northwest Biotherapeutics Inc.
  • Omeros Corp.
  • OncoSec Medical Inc.
  • Oncothyreon Inc.
  • Oramed Pharmaceuticals Inc.
  • Oxford BioMedica
  • Pain Therapeutics Inc.
  • Paratek Pharmaceuticals Inc.
  • Peregrine Pharmaceuticals Inc.
  • Pieris Pharmaceuticals Inc.
  • Sunesis Pharmaceuticals Inc.
  • Synergy Pharmaceuticals Inc.
  • Synta Pharmaceuticals Corp.
  • TG Therapeutics Inc.
  • Threshold Pharmaceuticals Inc.
  • Verastem Inc.

Recent Interviews

Panelists Select 19 Companies for the 2016 Small-Cap Biotech Watchlist (12/15/15)

In advance of the Biotech Showcase 2016, The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year.

Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading (6/24/15)

Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners. In this interview with The Life Sciences Report, Zavoico delineates some movers and shakers in the cancer immunotherapy field, and recommends investors keep their pencils sharp and eyes open as data emerge over the next year or two.

A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update (5/13/15)

It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.

Recent Quotes

"We expect to see reports on safety and efficacy from the first cohort of AST's cervical spinal cord injury trial starting sometime in Q2/16."

The Life Sciences Report Interview with George Zavoico (1/27/16)
more >

"Durable survival was reported in AST's small Phase 2 trial in acute myeloid leukemia."

The Life Sciences Report Interview with George Zavoico (12/16/15)
more >

"We are maintaining our Buy rating for AST."

— George Zavoico, JonesTrading (11/10/15)
more >

"We are initiating coverage of AST."

— George Zavoico, JonesTrading (10/8/15)
more >

"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases."

The Life Sciences Report Interview with George Zavoico (6/24/15)
more >

"We are raising our price target for OMER."

— George Zavoico, MLV & Co (2/18/15)
more >

"THLD's Phase 3 soft tissue sarcoma trial is likely to play out with topline results by Q3/15 or Q4/15."

The Life Sciences Report Interview with George Zavoico (1/27/15)
more >

"Our view [is] that THLD's TH-302 is a platform in a single drug."

— George Zavoico, MLV & Co (12/19/14)
more >

more comments

"GLPG is notable and underappreciated."

The Life Sciences Report Interview with George Zavoico (11/12/14)
more >

"Positive data in the pancreatic or the sarcoma studies could take THLD shares to my target."

The Life Sciences Report Interview with George Zavoico (11/12/14)
more >

"We see a pretty healthy revenue stream coming from OMER's Omidria."

The Life Sciences Report Interview with George Zavoico (11/12/14)
more >

"We believe that OMER will become profitable in 2016."

The Life Sciences Report Biotech Watchlist Update with George Zavoico (11/6/14)
more >

"We continue to believe OMER's OMS824 to be safe and expect the Phase 2 trial to resume."

— George Zavoico, MLV & Co (10/22/14)
more >

"We think THLD could become profitable in 2016 based on revenue from sales of TH-302."

— George Zavoico, MLV & Co (10/13/14)
more >

"I believe THLD's drug works, and momentum for the company is building."

The Life Sciences Report Interview with George Zavoico (3/6/14)
more >

"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space."

The Life Sciences Report Interview with George Zavoico (3/6/14)
more >

"Behind Omidria, OMER has a robust pipeline that has advanced into a number of phase 1 and phase 2 trials."

The Life Sciences Report Interview with George Zavoico (3/6/14)
more >

fewer comments

Due to permission requirements, not all quotes are shown.